Blog
Trinity: Deep Dive
The AI Context Layer: The Missing Link in AI-Ready Data
Trinity: Deep Dive A closer look at what powers commercialization decisions in life sciences Most commercial life sciences organizations have invested heavily in data. They have lakehouses, harmonized data feeds, and dashboard environments such as Power BI, Tableau, and Snowflake that their teams rely on every day. These tools already carry semantic models: metric definitions,…
Filter posts by:
Blog
CAR-Ts: Barriers and Opportunities for the Migration into Earlier Lines of Therapy in the USA
Although CAR Ts are on the cutting edge of oncology treatment, they are still only approved for administration following at least two other lines of treatment. Key barriers for CAR T migration into earlier lines include the complex logistics and site...
Blog
Ten Long-Term Impacts of COVID-19 on Biopharma
Written by Michaela Broadhurst, Olivia Gugliemini, Emily Lewis, and Tom Rutkowski
Blog
Access and Reimbursement: Access to Digital Therapeutics in a Post-COVID-19 World
Digital therapeutics (DTx) represent a novel approach to delivering improved clinical outcomes, but the unstructured nature of today’s DTx access process has presented a major hurdle to broader uptake.
Payers are still at very different stages in their acceptance of DTx, and...
Blog
2019 NRDL: Insights for Future Pricing Negotiations in China
China’s 2019 National Reimbursement Drug List (NRDL) update offers manufacturers key learnings and insights for future NRDL negotiations, particularly with respect to the negotiation tactics used in different disease areas; although in most disease areas the comparative negotiation rule was employed...
